Antilymphoma treatments given subsequent to yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: A review of the literature

Stephen M. Ansell*, Russell J. Schilder, Peter C. Pieslor, Leo I. Gordon, Christos Emmanouilides, Katie Vo, Myron S. Czuczman, Thomas E. Witzig, Charles Theuer, Arturo Molina

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Fingerprint

Dive into the research topics of 'Antilymphoma treatments given subsequent to yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: A review of the literature'. Together they form a unique fingerprint.

Medicine & Life Sciences